tradingkey.logo


Elanco Animal Health Inc

ELAN

14.070USD

+0.280+2.03%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
6.99BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
18.73P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Elanco Animal Health Inc āļšāļĢāļīāļĐāļąāļ—
Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ELAN
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Elanco Animal Health Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 20, 2018
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Jeffrey N. (Jeff) Simmons
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™9000
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Sep 20
āļ—āļĩāđˆāļ­āļĒāļđāđˆ2500 Innovation Way N
āđ€āļĄāļ·āļ­āļ‡GREENFIELD
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNYSE Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ46140-9163
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ18773526261
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.elanco.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ELAN
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļSep 20, 2018
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Jeffrey N. (Jeff) Simmons
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
150.03K
+26.80%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
99.26K
--
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
80.96K
--
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
79.40K
--
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Independent Director
Independent Director
74.50K
--
Mr. James Meer
Mr. James Meer
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
62.55K
-1.82%
Ms. Shiv O'Neill
Ms. Shiv O'Neill
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.92K
+100.82%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
150.03K
+26.80%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
99.26K
--
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
80.96K
--
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Pet Health
635.00M
53.23%
Farm Animal
546.00M
45.77%
Contract Manufacturing
12.00M
1.01%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
International
639.00M
53.56%
United States
554.00M
46.44%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Pet Health
635.00M
53.23%
Farm Animal
546.00M
45.77%
Contract Manufacturing
12.00M
1.01%
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 16 āļž.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 16 āļž.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Dodge & Cox
16.70%
PRIMECAP Management Company
10.11%
The Vanguard Group, Inc.
9.69%
Fidelity Management & Research Company LLC
7.71%
Black Creek Investment Management, Inc.
4.44%
Other
51.35%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Dodge & Cox
16.70%
PRIMECAP Management Company
10.11%
The Vanguard Group, Inc.
9.69%
Fidelity Management & Research Company LLC
7.71%
Black Creek Investment Management, Inc.
4.44%
Other
51.35%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
63.16%
Investment Advisor/Hedge Fund
32.92%
Hedge Fund
3.35%
Individual Investor
1.08%
Research Firm
1.01%
Sovereign Wealth Fund
0.79%
Pension Fund
0.77%
Bank and Trust
0.44%
Family Office
0.11%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
879
514.22M
103.54%
-39.32M
2025Q1
974
511.32M
102.96%
-71.50M
2024Q4
996
503.77M
101.85%
-80.73M
2024Q3
1000
494.48M
100.04%
-96.31M
2024Q2
1034
494.94M
100.16%
-92.98M
2024Q1
1051
494.01M
100.22%
-99.13M
2023Q4
1048
492.96M
100.04%
-103.67M
2023Q3
1055
493.54M
100.18%
-93.98M
2023Q2
1067
490.17M
99.54%
-75.35M
2023Q1
1071
498.03M
101.25%
-46.19M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Dodge & Cox
82.92M
16.7%
-260.08K
-0.31%
Mar 31, 2025
PRIMECAP Management Company
50.22M
10.11%
-941.63K
-1.84%
Mar 31, 2025
The Vanguard Group, Inc.
48.14M
9.69%
-437.73K
-0.90%
Mar 31, 2025
Fidelity Management & Research Company LLC
38.30M
7.71%
+9.79M
+34.35%
Mar 31, 2025
Black Creek Investment Management, Inc.
22.04M
4.44%
+1.61M
+7.87%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
20.46M
4.12%
+2.56M
+14.32%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.06M
4.04%
-618.85K
-2.99%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
15.98M
3.22%
+292.65K
+1.87%
Mar 31, 2025
Fidelity Institutional Asset Management
15.55M
3.13%
+3.83M
+32.70%
Mar 31, 2025
Shapiro Capital Management LLC
12.33M
2.48%
-24.38K
-0.20%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
SPDR S&P Pharmaceuticals ETF
3.83%
iShares U.S. Pharmaceuticals ETF
3.57%
First Trust Health Care Alphadex Fund
3.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.72%
First Trust NASDAQ Pharmaceuticals ETF
2.36%
Brandes US Small-Mid Cap Value ETF
2.14%
VanEck Agribusiness ETF
1.51%
First Trust Mid Cap Value AlphaDEX Fund
0.98%
Global X Adaptive US Factor ETF
0.72%
Federated Hermes MDT Large Cap Value ETF
0.7%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
SPDR S&P Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.83%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.57%
First Trust Health Care Alphadex Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.72%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.36%
Brandes US Small-Mid Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.14%
VanEck Agribusiness ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.51%
First Trust Mid Cap Value AlphaDEX Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.98%
Global X Adaptive US Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.72%
Federated Hermes MDT Large Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.7%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™